Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)
Grant Amount: Unspecified.
The National Institute of Mental Health invites research grant applications to develop innovative programs to advance therapeutics for NeuroAIDS. This Funding Opportunity Announcement (FOA) will support research programs that will advance central nervous system (CNS)-focused therapeutic approaches to: (a) address HIV-associated neurocognitive disorders in HIV-infected individuals on highly active anti-retroviral therapy (HAART), (b) eradicate persistent HIV-1 from the CNS during chronic infection, (c) prevent establishment of HIV-1 in the brain during early infection, and (d) assess the potential for CNS toxicity using HAART or candidate drugs that are currently in clinical studies to eradicate HIV-1. Studies to create or adapt existing animal models of HIV-1 infection in the CNS may be proposed to enable assessment of novel HIV CNS-focused therapeutic candidates. Multi-disciplinary, multi-project programs that are focused on improving neurocognition in HIV-infected persons are encouraged. A well defined, synergistic and milestone-driven plan for discovery, preclinical, and/or early clinical hypothesis-driven research should be presented. Public-private partnerships are encouraged but not required.
US Department of Health and Human Services Public Health Services National Institutes of Health National Institute of Mental Health
City Agencies Colleges/Universities Commercial Organizations Community Based Organizations County Agencies Educational Organizations/Institutions Federal Government Agencies IRS 501 (c)(3) Organizations Nonprofit Organizations Religious Organizations Schools State Agencies Tribal Organizations
Award Amount Notes
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. For applications proposing basic research exclusively throughout the 5 year term, up to $675,000 direct costs may be requested yearly. Applications proposing the use of large animals (e.g., non-human primates) may request up to $800,000 direct costs in any year(s) that such large animals will be needed and, for applications proposing pilot clinical studies, the budget may include up to $950,000 direct costs in any year(s) in which clinical studies are being conducted.
Antiretroviral Drugs Clinical Research Disease Prevention HIV Positive Persons Neurological Diseases or Disorders Vaccine Development Research
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Adobe_VerB.pdf), except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.